Business Context and Reporting Period
Company: Minerva Neurosciences, Inc. (NERV)
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2025
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) for a private placement of Series A Convertible Preferred Stock and warrants.
Key Financial Metrics and Capital Structure
Capital Raise Structure:
- Total Potential Proceeds: Up to $200 million.
- Initial Component: 80,000 shares of Series A Preferred Stock at $1,000 per share ($80 million).
- Tranche A Warrants: Immediately exercisable for up to 80,000 additional shares ($80 million) until the 10th day following the "Milestone Event" (successful Phase 3 primary endpoint announcement).
- Tranche B Warrants: Exercisable for up to 40,000 additional shares ($40 million) commencing on the earlier of the Milestone Event or the 3-year anniversary of closing; expires on the 4-year anniversary.
Security Terms:
- Conversion Price: $2.11 per share of Common Stock (subject to stockholder approval and beneficial ownership limits).
- Liquidation Preference: 2x the original per share price ($2,000) plus accrued dividends prior to stockholder approval; converts to pro-rata common stock treatment after approval.
- Redemption: If stockholder approval is not obtained within one year, holders may request redemption at the liquidation preference price.
Use of Proceeds: Financing the confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia (including upsizing), preparation and resubmission of the New Drug Application (NDA), commercial launch readiness, and working capital.
Material Changes and Corporate Actions
Board and Governance Changes:
- The Board of Directors will be expanded to include up to three directors designated by Vivo Capital LLC.
- A Scientific Advisory Board (SAB) will be constituted to advise on the Phase 3 trial, with members mutually agreed upon by the Company and Vivo Capital LLC.
Stockholder Support:
Certain stockholders have entered into Support Agreements to vote in favor of the issuance of Common Stock upon conversion of the Series A Preferred Stock and other related proposals.
Registration Rights:
The Company agreed to file a Form S-3 registration statement within 15 days of stockholder approval to allow investors to resell shares.
Outlook, Risks, and Contingencies
Key Milestone Dependency:
The exercise of Tranche A warrants is contingent on the public announcement of the "Milestone Event" (statistically significant primary endpoint achievement in the Phase 3 trial of roluperidone). Tranche B warrants also hinge on this event or a time-based trigger.
Short Sale Restrictions:
Warrants are subject to forfeiture if investors engage in short sales of the Company's securities within 48 months of closing.
Regulatory and Approval Risks:
- Conversion of Preferred Stock to Common Stock is contingent on stockholder approval.
- Redemption rights are triggered if stockholder approval is not obtained within one year.
- Success of the capital raise and future liquidity depends on the clinical success of roluperidone.
Investor Verification Checklist
- Closing Date: Verify the actual closing date (expected on or around October 23, 2025) and confirmation of the $80 million initial receipt.
- Stockholder Approval: Monitor the timeline for the special meeting to approve the issuance of Common Stock upon conversion; failure to approve within one year triggers redemption rights.
- Phase 3 Trial Status: Track the progress and results of the roluperidone Phase 3 confirmatory trial, as this dictates the exercisability of the $120 million in warrant tranches.
- Dilution Impact: Assess the potential dilution from the conversion of 80,000 preferred shares plus up to 120,000 warrant shares at the $2.11 conversion price.
- Board Composition: Confirm the appointment of the three Vivo Capital-designated directors and the formation of the Scientific Advisory Board.